E
Enfortumab Vedotin
Availability of ACE Drug Guidance
No
Biologics Drug Information Overview
Yes
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Active ingredient: Enfortumab Vedotin
General information
Subsidy Information and Financing Scheme
[MSHL] Enfortumab vedotin Powder For Concentrate For Solution For Infusion 20 mg, 30 mg
Treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
Drug Guidance for Subsidy
Not Applicable
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Padcev® Powder For Concentrate For Solution For Infusion 20 mg |
|
Padcev® Powder For Concentrate For Solution For Infusion 30 mg |
|